Nutrition and the HIV-associated lipodystrophy syndrome

Area of Science:

• Nutrition and Metabolism
• HIV/AIDS Management
• Cardiovascular Health

Background:

• HIV-associated lipodystrophy syndrome (HALS) involves metabolic and morphological changes, a known side effect of highly active antiretroviral therapy (HAART).
• Limited evidence currently exists on nutrition's role in managing HALS systemic parameters.
• HALS prevalence varies widely (9-83%) due to inconsistent definitions and assessment methods.

Purpose of the Study:

• To review current knowledge on HALS, focusing on nutrition's role in mitigating its systemic parameters.
• To explore the potential of lifestyle interventions, particularly diet, as a safe and effective management strategy for HALS.

Main Methods:

• Literature review of existing studies on HALS, its causes, and management.
• Analysis of the impact of nutritional interventions on morphological and metabolic alterations associated with HALS.
• Evaluation of the safety and tolerability of lifestyle interventions compared to pharmacological and surgical options.

Main Results:

• HALS presents with lipoatrophy, lipohypertrophy, dyslipidemia, glucose intolerance, and increased cardiovascular disease (CVD) risk.
• Adipocyte inflammation, oxidative stress, and mitochondrial toxicity are central to HALS development, making adipocytes a potential treatment target.
• A Mediterranean-style diet has demonstrated effectiveness in improving HALS parameters.
• n-3 PUFA supplementation shows encouraging results, warranting further investigation.

Conclusions:

• Targeted lifestyle interventions, such as a Mediterranean diet and n-3 PUFA supplementation, offer a safe and tolerable approach to managing HALS.
• These nutritional strategies can effectively improve the metabolic and morphological alterations associated with HALS.
• Further randomized controlled trials are justified to confirm the benefits of n-3 PUFA in HALS management.